Publications by authors named "Maria S Garcia-Gutierrez"

Cirrhosis incidence is significantly increased with age and frequently complicated with neurocognitive dysfunction. We have evaluated the contribution of aging to neuroinflammation in the liver-brain axis in advanced chronic liver disease. Young (6-week-old) and old (9-month-old) mice were included in a 12-week protocol of CCl-induced cirrhosis.

View Article and Find Full Text PDF

Spinal opioids have mixed efficacy and their adverse effects force treatment cessation of postoperative pain. Consequently, there is an ongoing search for new therapeutic strategies. Here, we evaluated the analgesic efficacy of intrathecal UCM707, an anandamide reuptake inhibitor, and morphine combination.

View Article and Find Full Text PDF

Postoperative pain (POP) is a challenging clinical phenomenon that affects the majority of surgical patients and demands effective management to mitigate adverse outcomes such as persistent pain. The primary goal of POP management is to alleviate suffering and facilitate a seamless return to normal function for the patient. Despite compelling evidence of its drawbacks, opioid analgesia remains the basis of POP treatment.

View Article and Find Full Text PDF

Migraine is a highly prevalent neurological disorder. Among the risk factors identified, psychiatric comorbidities, such as depression, seem to play an important role in its onset and clinical course. Patients with migraine are 2.

View Article and Find Full Text PDF

Adolescence is a critical period for brain maturation in which this organ undergoes critical plasticity mechanisms that increase its vulnerability to the effects of alcohol. Significantly, ethanol-induced disruption of hippocampal neurogenesis has been related to cognitive decline in adulthood. During adolescence, the maturation of perineuronal nets (PNNs), extracellular matrix structures highly affected by ethanol consumption, plays a fundamental role in neurogenesis and plasticity in the hippocampus.

View Article and Find Full Text PDF

The cognitive decline in people with substance use disorders is well known and can be found during both the dependence and drug abstinence phases. At the clinical level, cognitive decline impairs the response to addiction treatment and increases dropout rates. It can be irreversible, even after the end of drug abuse consumption.

View Article and Find Full Text PDF

This study aims to further characterize cannabidiol's pharmacological and molecular profile as an antidepressant. Effects of cannabidiol (CBD), alone or combined with sertraline (STR), were evaluated in male CD1 mice ( = 48) exposed to an unpredictable chronic mild stress (UCMS) procedure. Once the model was established (4 weeks), mice received CBD (20 mg·kg-1, i.

View Article and Find Full Text PDF

The increasing prevalence of cognitive dysfunction and dementia in developed countries, associated with population aging, has generated great interest in characterizing and quantifying cognitive deficits in these patients. An essential tool for accurate diagnosis is cognitive assessment, a lengthy process that depends on the cognitive domains analyzed. Cognitive tests, functional capacity scales, and advanced neuroimaging studies explore the different mental functions in clinical practice.

View Article and Find Full Text PDF

Cumulative evidence has pointed out cannabinoid CB2 receptors (CBr) as a potential therapeutic key target for treating alcohol use disorder (AUD). This review provides the most relevant results obtained from rodent and human studies, including an integrative section focused on the involvement of CBr in the neurobiology of alcohol addiction. A literature search was conducted using the electronic databases Medline and Scopus for articles.

View Article and Find Full Text PDF

The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions.

View Article and Find Full Text PDF

Emotional behavior, memory, and learning have been associated with alterations in the immune system in neuropsychiatric and neurodegenerative diseases. In recent years, several studies pointed out the involvement of the cannabinoid receptor 2 (CB2r) in the immune system and the regulation of inflammation. This receptor is widely distributed in different tissues and organs with higher expression in spleen and immune system cells.

View Article and Find Full Text PDF
Article Synopsis
  • Several studies have investigated cannabidiol (CBD) for its potential to reduce anxiety and depression, although the exact biological mechanisms are still not fully understood.
  • In experiments with 130 male mice, different doses of CBD were tested for their effects on anxiety and depressive-like behaviors, revealing that a dose of 20 mg/kg was most effective in wild-type mice, while the anxiolytic effects were absent in mice lacking the CB1 cannabinoid receptor.
  • Additionally, changes in gene expression related to cannabinoid receptors and GABA(A) subunits were observed, suggesting that CBD operates through complex pathways in the brain that vary by dose and brain region.
View Article and Find Full Text PDF

Despite substance use disorders (SUD) being one of the leading causes of disability and mortality globally, available therapeutic approaches remain ineffective. The difficulty in accurately characterizing the neurobiological mechanisms involved with a purely qualitative diagnosis is an obstacle to improving the classification and treatment of SUD. In this regard, identifying central and peripheral biomarkers is essential to diagnosing the severity of drug dependence, monitoring therapeutic efficacy, predicting treatment response, and enhancing the development of safer and more effective pharmacological tools.

View Article and Find Full Text PDF

The pharmacological modulation of the cannabinoid receptor 2 (CB2r) has emerged as a promising potential therapeutic option in addiction. The purpose of this review was to determine the functional involvement of CB2r in the effects produced by drugs of abuse at the central nervous system (CNS) level by assessing evidence from preclinical and clinical studies. In rodents, several reports suggest the functional involvement of CB2r in the effects produced by drugs of abuse such as alcohol, cocaine, or nicotine.

View Article and Find Full Text PDF

Drug treatments available for the management of substance use disorders (SUD) present multiple limitations in efficacy, lack of approved treatments or alarming relapse rates. These facts hamper the clinical outcome and the quality of life of the patients supporting the importance to develop new pharmacological agents. Lately, several reports suggest that cannabidiol (CBD) presents beneficial effects relevant for the management of neurological disorders such as epilepsy, multiple sclerosis, Parkinson's, or Alzheimer's diseases.

View Article and Find Full Text PDF

Nowadays, cannabis is the most consumed illicit drug. The global prevalence of the use of cannabis in 2017 was estimated in 188 million of people, 3.8% of worldwide population.

View Article and Find Full Text PDF

The potential therapeutic use of some plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC.

View Article and Find Full Text PDF
Article Synopsis
  • Addiction management requires a comprehensive bio-psycho-social approach to identify the transition from substance use to dependence and improve prevention, treatment, and recovery efforts.
  • The review focuses on findings from neuropsychophysiological research, particularly event-related potentials (ERPs), to explore cognitive domains involved in alcohol dependence, such as incentive salience, negative emotionality, and executive functioning.
  • New psychophysiological tools, such as brain connectivity analysis, show promise in understanding the disrupted brain circuits and cognitive processes associated with alcohol dependence, offering potential clinical markers and treatments.
View Article and Find Full Text PDF

During the last years, an extraordinary effort has been made to identify biomarkers as potential tools for improving prevention, diagnosis, drug response and drug development in psychiatric disorders. Contrary to other diseases, mental illnesses are classified by diagnostic categories with a broad variety list of symptoms. Consequently, patients diagnosed from the same psychiatric illness present a great heterogeneity in their clinical presentation.

View Article and Find Full Text PDF
Article Synopsis
  • - The article discusses the challenge of accurately diagnosing psychiatric disorders due to their high variability and the importance of finding biomarkers for personalized treatment, focusing on the endocannabinoid system (ECS) that affects emotions and cognition.
  • - It reviews studies on the ECS in animal models and clinical research, highlighting how manipulating cannabinoid receptors or their degrading enzymes can influence mood disorders, PTSD, and other psychiatric conditions.
  • - Findings suggest a significant role for cannabinoid receptor 1 (CB1r) in stress and mood regulation, pointing towards potential therapeutic benefits of targeting the ECS, though more clinical research is required to confirm these biomarkers' effectiveness.
View Article and Find Full Text PDF